ERAXIS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eraxis, and what generic alternatives are available?
Eraxis is a drug marketed by Vicuron Holdings and is included in one NDA.
The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.
Summary for ERAXIS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 56 |
Clinical Trials: | 11 |
Patent Applications: | 3,160 |
Drug Prices: | Drug price information for ERAXIS |
What excipients (inactive ingredients) are in ERAXIS? | ERAXIS excipients list |
DailyMed Link: | ERAXIS at DailyMed |
Recent Clinical Trials for ERAXIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Texas Tech University Health Sciences Center | Phase 4 |
University of Texas Southwestern Medical Center | Phase 4 |
National Center for Research Resources (NCRR) | Phase 4 |
Pharmacology for ERAXIS
Drug Class | Echinocandin Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for ERAXIS
US Patents and Regulatory Information for ERAXIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ERAXIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ERAXIS
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Europe MA EEIG | Ecalta | anidulafungin | EMEA/H/C/000788 Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years. |
Authorised | no | no | no | 2007-09-20 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ERAXIS
See the table below for patents covering ERAXIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 69331922 | ⤷ Sign Up | |
Taiwan | 200400831 | Antifungal parenteral products | ⤷ Sign Up |
South Korea | 100256036 | ⤷ Sign Up | |
Norway | 930948 | ⤷ Sign Up | |
Russian Federation | 2129562 | CYCLIC PEPTIDE DERIVATIVES OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ERAXIS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0561639 | SPC002/2008 | Ireland | ⤷ Sign Up | SPC002/2008: 20081105, EXPIRES: 20180317 |
0561639 | C00561639/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009 |
0561639 | 91406 | Luxembourg | ⤷ Sign Up | 91406, EXPIRES: 20180318 |
0561639 | SPC/GB08/016 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920 |
0561639 | C300334 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |